A new profoundly reversible alkaloid and ChE-I, Huperzine A (Hup A), is separated from Huperzia Serrata. It selectively inhibits acetylcholinesterase action and thus promotes increased acetylcholine levels in the brain, enhancing cognitive function in patients with dementia. Huperzine A was first recommended in China in 1994 for the treatment of Alzheimer’s disease.

Some researches have shown that Huperzine A causes a meaningful increase in memory in the elderly and in patients with AD or VR. Furthermore, animal and human security evaluations have shown that Huperzine A does not have expected toxicity.

When it gets compared to galantamine, donepezil, tacrine, etc., it has a harder continuation of an action, better diffusion of the blood-brain barrier, more inclusive oral bioavailability, fewer side consequences, and many more advantages.

The aging of the world community has developed quickly in recent decades and dementia is growing a global problem. Also, the Alzheimer’s disease (AD) and vascular dementia (VR) are the principal agents of dementia at the end of growth and affect about 10% of people 65 years of age and older.

Alzheimer’s disease is a devastating, generalized, age-related neurodegenerative disease, the main manifestation of which is undermined memory with reduced life skills. The main center for the significant practice of Alzheimer’s disease is currently based on cholinergic development plans.

Increased cholinergic neurotransmission handling cholinesterase inhibitors (ChE-Is) leads to a slight enhancement in cognitive function in some patients. VR is a type of dementia prompted by several cerebrovascular complications, such as cerebral injury, cerebral infarction, and subarachnoid hemorrhage.

Interestingly, cholinergic agents, including ChE-Is, have shown significant benefits in RV therapy. Therefore, ChE-Is is the standard remedy for the processing of patients with Alzheimer’s disease and VR. Although many clinical subjects have shown that Huperzine A appears to give privileges without severe side effects for some cases with Alzheimer’s disease or VR.

A report showed that there was no conclusive evidence that Huperzine A was beneficial to Alzheimer’s disease or DV. Further analysis of Huperzine A for Alzheimer’s disease revealed that although the available studies showed some benefit of Huperzine A, the studies were generally small and of limited quality.